Compare FXNC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | MDWD |
|---|---|---|
| Founded | 1907 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.5M | 212.1M |
| IPO Year | 2012 | 2013 |
| Metric | FXNC | MDWD |
|---|---|---|
| Price | $28.30 | $14.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 55.0K | ★ 99.1K |
| Earning Date | 05-12-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 96.00 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $7,717,000.00 | N/A |
| Revenue This Year | $12.21 | $48.92 |
| Revenue Next Year | $2.93 | $35.04 |
| P/E Ratio | $50.96 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $18.35 | $13.54 |
| 52 Week High | $29.85 | $22.00 |
| Indicator | FXNC | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 35.00 |
| Support Level | $26.39 | N/A |
| Resistance Level | $28.68 | $18.49 |
| Average True Range (ATR) | 0.72 | 0.67 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 82.91 | 20.79 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.